What Is ePRO and Why Clinical Trials in CEE Need It Now

We built Medify because of a gap that shouldn't exist. ePRO lets patients record symptoms, medication adherence, and quality-of-life data directly through their phones during a trial. It has been standard in Western Europe and North America for over a decade. In Central and Eastern Europe, most sites still use paper diaries.

Why ePRO matters now

The global ePRO analytics market reached an estimated $1.83 billion in 2025, growing at a 15.5% compound annual growth rate with projections to $3.25 billion by 2029, driven primarily by the rise of decentralized clinical trials and the demand for real-time patient data.^[1]

Regulators are accelerating this shift. The FDA finalized its guidance on Core Patient-Reported Outcomes in Cancer Clinical Trials in October 2024, followed by PFDD Guidance 3 on fit-for-purpose clinical outcome assessments in October 2025. The EMA has launched parallel initiatives on patient-centric evidence in benefit-risk assessments. Together they move PRO endpoints toward the center of regulatory strategy.^[2]

What ePRO replaces

In traditional clinical trials, patients record symptoms in paper diaries. The problems with this approach are well documented. Research has shown substantial bias in summary recall, with patients influenced by how they feel at the time of rating rather than their actual experience over the assessment period. Paper diaries also suffer from undocumented compliance. Without timestamps, there is no way to verify when entries were actually made.^[3]

ePRO systems solve both problems. Electronic diaries automatically timestamp all entries, restrict data entry to predefined time windows, allow only valid in-range entries, and can send reminders when entries are due. ePRO applications typically achieve compliance rates of over 80%, often exceeding 90%.^[3]

The gap we set out to close

When we started Medify in 2024, we interviewed 27 clinical trial experts across 43 in-depth conversations. The pattern was consistent: CEE sites want ePRO but can't access it. The platforms that dominate globally are priced for top-20 pharma budgets, take 6 to 12 months to deploy, and treat CEE localization as an afterthought.

We didn't build Medify to add another ePRO vendor to the market. We built it because the existing vendors don't serve this region. What they don't offer is a Cyrillic-first interface, an offline-first architecture for sites with unreliable connectivity, a deployment under six months, or pricing that works for a five-site Phase II study in Sofia.

What to look for in a CEE platform

• Native localization

  Cyrillic script support, local language interfaces, and culturally adapted patient communication are not optional. They directly affect compliance and data quality.

• Offline-first architecture

  Many CEE sites operate with inconsistent connectivity. An ePRO system that requires constant connection will produce data gaps.

• Regulatory alignment built in

  ICH-GCP E6(R3), EU Annex 11, GDPR and EU CTR 536/2014 compatibility should be architectural decisions, not configuration options.

The first-mover window

We've seen this firsthand. In our MVP pilot testing, sites that had never used ePRO before achieved 78% daily active patient usage and 90% data quality scores within the first month. They picked up the technology without difficulty. What had been missing was a platform they could get hold of in the first place.